Assignee
Baxalta GmbH
CH·24 granted patents·5 pending applications·84 citations·filing 2012–2020
Top patents by PatentIndex Score
29 records- 0196US10800816B2TFPI inhibitors and methods of useBaxalta GmbH·Filed 2017·Granted Oct 13, 2020·10 cites·25 claims
- 0293US10201586B2TFPI inhibitors and methods of useBaxalta GmbH·Filed 2016·Granted Feb 12, 2019·10 cites·17 claims
- 0386US9358181B2Assembly to facilitate user reconstitutionBaxalta GmbH·Filed 2013·Granted Jun 7, 2016·12 cites·20 claims
- 0482US11001613B2TFPI inhibitors and methods of useBaxalta GmbH·Filed 2017·Granted May 11, 2021·1 cites·33 claims
- 0577US9465037B2Characterization of CHO-MIF gene and protein, and use thereofBaxalta GmbH·Filed 2012·Granted Oct 11, 2016·2 cites·29 claims
- 0676USD893046SContainer unitBaxalta GmbH·Filed 2018·Granted Aug 11, 2020·13 cites·1 claims
- 0775US10900979B2Methods for testing effectiveness of a von Willebrand factor used in treating von Willebrand disease (VWD)Baxalta GmbH·Filed 2019·Granted Jan 26, 2021·0 cites·23 claims
- 0872US10745672B2Method of producing a polypeptide or virus of interest in a continuous cell cultureBaxalta GmbH·Filed 2019·Granted Aug 18, 2020·0 cites·20 claims
- 0972US9873720B2TFPI inhibitors and methods of useBaxalta GmbH·Filed 2014·Granted Jan 23, 2018·1 cites·4 claims
- 1072US9777051B2TFPI inhibitors and methods of useBaxalta GmbH·Filed 2013·Granted Oct 3, 2017·1 cites·10 claims
- 1170US9670456B2Virus filtration of cell culture mediaBaxalta GmbH·Filed 2013·Granted Jun 6, 2017·1 cites·19 claims
- 1269US10221400B2Method of producing a polypeptide or virus of interest in a continuous cell cultureBaxalta GmbH·Filed 2017·Granted Mar 5, 2019·0 cites·21 claims
- 1368US10696731B2Oligopeptide-free cell culture mediaBaxalta GmbH·Filed 2017·Granted Jun 30, 2020·0 cites·18 claims
- 1467US9889248B2Syringe storage trayBaxalta GmbH·Filed 2012·Granted Feb 13, 2018·6 cites·21 claims
- 1566US9650612B2Method of producing a polypeptide or virus of interest in a continuous cell cultureBaxalta GmbH·Filed 2013·Granted May 16, 2017·0 cites·16 claims
- 1665US9958456B2OxMIF as a diagnostic markerBaxalta GmbH·Filed 2012·Granted May 1, 2018·1 cites·11 claims
- 1765US9808570B2Syringe storage trayBaxalta GmbH·Filed 2013·Granted Nov 7, 2017·4 cites·1 claims
- 1861US2020207840A1Detection of cho-mif contaminationsBaxalta GmbH·Filed 2020·Application pending·0 cites
- 1959USD886611SContainer unitBaxalta GmbH·Filed 2018·Granted Jun 9, 2020·7 cites·1 claims
- 2059US10233436B2ADAMTS13-containing compositions having thrombolytic activityBaxalta GmbH·Filed 2013·Granted Mar 19, 2019·0 cites·14 claims
- 2159US2017260498A1Virus filtration of cell culture mediaBaxalta GmbH·Filed 2017·Application pending·0 cites
- 2256USD890358SContainer unitBaxalta GmbH·Filed 2018·Granted Jul 14, 2020·6 cites·1 claims
- 2352US10626166B2Detection of CHO-MIF contaminationsBaxalta GmbH·Filed 2015·Granted Apr 21, 2020·0 cites·12 claims
- 2450USD881577SCarrying caseBaxalta GmbH·Filed 2018·Granted Apr 21, 2020·4 cites·1 claims
- 2547USD898342SCarrying caseBaxalta GmbH·Filed 2018·Granted Oct 13, 2020·4 cites·1 claims
- 2646US2017240867A1Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivativesBaxalta GmbH·Filed 2015·Application pending·0 cites
- 2745US2017226487A1Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expressionBaxalta GmbH·Filed 2017·Application pending·0 cites
- 2835US2018155419A1Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant rasBaxalta GmbH·Filed 2016·Application pending·0 cites
- 2933USD878763SCarrying caseBaxalta GmbH·Filed 2018·Granted Mar 24, 2020·1 cites·1 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →